Would you take a medication that would help you lose weight? That’s the question many Americans have been considering since a class of drugs known as GLP-1s (newer brands include Mounjaro, Ozempic, and Wegovy) became popularized by celebrities and influencers earlier this year.
According to the latest Ipsos Consumer Tracker, over half (54%) of Americans are interested in medication to help them lose weight. With two new GLP-1s now FDA approved for weight loss, there are broader implications for sectors from healthcare to food & beverage to airlines if America can find ways to treat its epidemics of obesity.
Join our Ipsos experts as we dive into the implications of new obesity treatments, including:
- What Americans believe about obesity, and how that differs by demographics
- What Americans are discussing about obesity and obesity treatments
- Equity considerations regarding access to these treatments
- Implications for a broad set of industries
Registering will also ensure you receive a direct link to the recording once published, and notification of future events or Ipsos thought leadership on this topic.
Scott Morano, SVP, Ipsos Healthcare
Chareen Lim, SVP Ipsos Healthcare
Steve Girling, President Ipsos Healthcare